Janssen Biotech, Inc.

Morphosys Ag

Boehringer Ingelheim International Gmbh

Pfizer Corporation

Centocor Ortho Biotech Inc.

Gpc Biotech Ag

Robert Rauchenberger

Raymond W Sweet

Mark Hilary Cunningham

Jinquan Luo

Sheng-Jiun Wu

Jacqueline Benson

Jill Carton

Yevgeniya Orlovsky

Mark Rutz

Alexey Teplyakov

Robert T Sarisky

Lani Rose San Mateo

Fang Teng

Yiqing Feng

Katharine Heeringa

Eric Borges

Vedrana Stojanovic-Susulic

Paul Adam

Gabriela Wochnik-Veltrup

Francis Dodeller

Juan C Almagro

Michael Naso

Gregory John Carven

Michael Tesar

Thomas J Malia

Galina Obmolova

Elisabeth Thomassen-Wolf

Robert Arch

Dirk Ponsel

Shinji Ogawa

Zoltan Nagy

Jun Kuai

Lydia Mosyak

Susann Taudte

Daniela Della Ducata

Merle Elloso

Bingyuan Wu

Linda Wu

Christoph Brunner

Lani San Mateo

Yevgeniya I Orlovsky

Thomas Malia

Juan Carlos Almagro

A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Medical device for administering anti-IL-23 antibodies

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Anti-IGF antibodies

Methods of treatment using human anti-IL-23 antibodies

This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.

Antibodies targeting M-CSF

Human anti-IL-23 antibodies, compositions, methods and uses

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist

Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists

Toll-like receptor 3 antagonists

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.

Platelet-derived growth factor B specific antibodies and compositions and uses thereof

Polynucleotides encoding Toll-Like Receptor 3 antagonists

Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies

Growing community of inventors

Farchant, Germany

Robert Rauchenberger